gabapentin has been researched along with Complex Partial Epilepsy in 18 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 7.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Gabapentin (GBP) is a non-protein-bound gamma amino acid which is not subjected to metabolic degradation in man." | 6.68 | Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. ( Ben-Menachem, E; Hamberger, A; Hedner, T; Persson, LI; Söderfelt, B, 1995) |
| " The second patient complained of impotence after a rash while taking phenytoin and carbamazepine." | 3.70 | Improved sexual function in three men taking lamotrigine for epilepsy. ( Carwile, ST; Husain, AM; Miller, PP; Radtke, RA, 2000) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 3.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Gabapentin (GBP) is a non-protein-bound gamma amino acid which is not subjected to metabolic degradation in man." | 2.68 | Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. ( Ben-Menachem, E; Hamberger, A; Hedner, T; Persson, LI; Söderfelt, B, 1995) |
| "Gabapentin appears to increase human brain GABA levels." | 2.68 | The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. ( Behar, KL; Lamoureux, D; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| "Gabapentin was well tolerated by patients in both dosage groups, and no patients exited the study due to adverse events, despite rapid initiation of full dose within 24 hours." | 2.68 | Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. ( Bergey, GK; Blume, WT; Crockatt, JG; Garofalo, E; LaMoreaux, L; Leiderman, DB; Morrell, MJ; Morris, HH; Penovich, PE; Pierce, M; Rosenfeld, W, 1997) |
| " Results of outcome measures, including time to exit, completion rate, and mean time on monotherapy, showed no significant differences among dosage groups." | 2.68 | Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. ( Abou-Khalil, B; Beydoun, A; Cantrell, D; Fischer, J; Garofalo, E; Greiner, M; Harden, C; Hayes, A; Labar, DR; Pierce, M; Ramsay, RE; Sackellares, JC; Uthman, BM, 1997) |
| "Gabapentin is an anti-epileptic drug (AED) that was approved in 1993 for the adjunct treatment of complex partial seizures (CPS) with and without generalization." | 2.41 | Gabapentin: a unique anti-epileptic agent. ( Dougherty, JA; Rhoney, DH, 2001) |
| "Gabapentin has been accepted worldwide as a novel antiepileptic drug with a favourable tolerability profile." | 1.30 | Isolated ataxia as an idiosyncratic side-effect under gabapentin. ( Bittermann, HJ; Herrendorf, G; Kurth, C; Steinhoff, BJ, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (72.22) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crespo Pérez, L | 1 |
| Moreira Vicente, V | 1 |
| Cano Ruiz, A | 1 |
| Gobernado Serrano, JM | 1 |
| Cobo Ibañez, N | 1 |
| Milicua Salamero, JM | 1 |
| Petroff, OA | 3 |
| Hyder, F | 1 |
| Rothman, DL | 2 |
| Mattson, RH | 3 |
| Wolf, SM | 1 |
| Shinnar, S | 1 |
| Kang, H | 1 |
| Gil, KB | 1 |
| Moshé, SL | 1 |
| Short, C | 1 |
| Cooke, L | 1 |
| Fromm, GH | 1 |
| Ben-Menachem, E | 1 |
| Söderfelt, B | 1 |
| Hamberger, A | 1 |
| Hedner, T | 1 |
| Persson, LI | 1 |
| Behar, KL | 1 |
| Lamoureux, D | 1 |
| Tallian, KB | 1 |
| Nahata, MC | 1 |
| Lo, W | 1 |
| Tsao, CY | 1 |
| Bergey, GK | 1 |
| Morris, HH | 2 |
| Rosenfeld, W | 1 |
| Blume, WT | 1 |
| Penovich, PE | 1 |
| Morrell, MJ | 1 |
| Leiderman, DB | 1 |
| Crockatt, JG | 1 |
| LaMoreaux, L | 1 |
| Garofalo, E | 2 |
| Pierce, M | 2 |
| Beydoun, A | 1 |
| Fischer, J | 1 |
| Labar, DR | 1 |
| Harden, C | 1 |
| Cantrell, D | 1 |
| Uthman, BM | 1 |
| Sackellares, JC | 1 |
| Abou-Khalil, B | 1 |
| Ramsay, RE | 1 |
| Hayes, A | 1 |
| Greiner, M | 1 |
| Pierce, MW | 2 |
| Shokry, A | 1 |
| Steinhoff, BJ | 1 |
| Herrendorf, G | 1 |
| Bittermann, HJ | 1 |
| Kurth, C | 1 |
| Hamer, HM | 1 |
| Dodrill, CB | 1 |
| Arnett, JL | 1 |
| Hayes, AG | 1 |
| Garofalo, EA | 1 |
| Greeley, CA | 1 |
| Greiner, MJ | 1 |
| Maj, R | 1 |
| Fariello, RG | 1 |
| Pevarello, P | 1 |
| Varasi, M | 1 |
| McArthur, RA | 1 |
| Salvati, P | 1 |
| Husain, AM | 1 |
| Carwile, ST | 1 |
| Miller, PP | 1 |
| Radtke, RA | 1 |
| Collins, TL | 1 |
| Dougherty, JA | 1 |
| Rhoney, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
3 reviews available for gabapentin and Complex Partial Epilepsy
| Article | Year |
|---|---|
[Anticonvulsant hypersensitivity syndrome: an entity to be remembered].
Topics: Adolescent; Amines; Anemia, Hemolytic; Anticonvulsants; Astrocytoma; Brain Neoplasms; Carbamazepine; | 2009 |
Gabapentin: discussion.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drugs, Inv | 1994 |
Gabapentin: a unique anti-epileptic agent.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy, Complex Part | 2001 |
6 trials available for gabapentin and Complex Partial Epilepsy
| Article | Year |
|---|---|
Gabapentin toxicity in children manifesting as behavioral changes.
Topics: Acetates; Affect; Aggression; Amines; Anticonvulsants; Behavior; Child; Cyclohexanecarboxylic Acids; | 1995 |
Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Respon | 1995 |
The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response | 1996 |
Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Rel | 1997 |
Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecar | 1997 |
Cognitive abilities and adjustment with gabapentin: results of a multisite study.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Epilepsy | 1999 |
9 other studies available for gabapentin and Complex Partial Epilepsy
| Article | Year |
|---|---|
Brain homocarnosine and seizure control of patients taking gabapentin or topiramate.
Topics: Adult; Amines; Anticonvulsants; Brain Chemistry; Carnosine; Cyclohexanecarboxylic Acids; Drug Therap | 2006 |
Hypomania induced by gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Dose-Response Rela | 1995 |
Gabapentin associated with aggressive behavior in pediatric patients with seizures.
Topics: Acetates; Adolescent; Age Factors; Aggression; Amines; Anticonvulsants; Child; Child Behavior Disord | 1996 |
[Trials with gabapentin monotherapy in patients with complex partial or secondary generalized seizures].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Do | 1997 |
Isolated ataxia as an idiosyncratic side-effect under gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cerebellar Ataxia; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Successful treatment with gabapentin in the presence of hypersensitivity syndrome to phenytoin and carbamazepine: a report of three cases.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Hypersens | 1999 |
Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures.
Topics: Acetates; Alanine; Amines; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Benzylamines; Carba | 1999 |
Improved sexual function in three men taking lamotrigine for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; | 2000 |
A comparison of four new antiepileptic medications.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose | 2000 |